Esperion Therapeutics Inc. (NASDAQ: ESPR)’s stock price has gone rise by 4.18 in comparison to its previous close of 3.11, however, the company has experienced a 20.90% increase in its stock price over the last five trading days. Schwab Network reported 2024-04-01 that Esperion Therapeutics (ESPR) specializes in cholesterol lowering medications. President and CEO Sheldon Koenig joins Nicole Petallides to give an overview of the company.
Is It Worth Investing in Esperion Therapeutics Inc. (NASDAQ: ESPR) Right Now?
ESPR has 36-month beta value of 0.79. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ESPR is 168.54M, and currently, short sellers hold a 10.48% ratio of that float. The average trading volume of ESPR on April 08, 2024 was 6.65M shares.
ESPR’s Market Performance
The stock of Esperion Therapeutics Inc. (ESPR) has seen a 20.90% increase in the past week, with a 31.71% rise in the past month, and a 40.56% gain in the past quarter. The volatility ratio for the week is 12.13%, and the volatility levels for the past 30 days are at 10.79% for ESPR. The simple moving average for the past 20 days is 34.47% for ESPR’s stock, with a 87.52% simple moving average for the past 200 days.
ESPR Trading at 32.94% from the 50-Day Moving Average
After a stumble in the market that brought ESPR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -4.71% of loss for the given period.
Volatility was left at 10.79%, however, over the last 30 days, the volatility rate increased by 12.13%, as shares surge +42.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +59.61% upper at present.
During the last 5 trading sessions, ESPR rose by +20.90%, which changed the moving average for the period of 200-days by +111.76% in comparison to the 20-day moving average, which settled at $2.46. In addition, Esperion Therapeutics Inc. saw 8.36% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ESPR starting from Warren Eric, who sale 742 shares at the price of $1.25 back on Sep 20 ’23. After this action, Warren Eric now owns 68,318 shares of Esperion Therapeutics Inc., valued at $924 using the latest closing price.
Warren Eric, the Chief Commercial Officer of Esperion Therapeutics Inc., sale 243 shares at $1.41 during a trade that took place back on Aug 18 ’23, which means that Warren Eric is holding 69,060 shares at $344 based on the most recent closing price.
Stock Fundamentals for ESPR
Current profitability levels for the company are sitting at:
- -1.34 for the present operating margin
- 0.63 for the gross margin
The net margin for Esperion Therapeutics Inc. stands at -2.04. The total capital return value is set at -3.14.
Based on Esperion Therapeutics Inc. (ESPR), the company’s capital structure generated 6.49 points at debt to capital in total, while cash flow to debt ratio is standing at -0.25. The debt to equity ratio resting at -1.18. The interest coverage ratio of the stock is 1767.76.
Currently, EBITDA for the company is -155.4 million with net debt to EBITDA at -2.97. When we switch over and look at the enterprise to sales, we see a ratio of 8.69. The receivables turnover for the company is 2.4for trailing twelve months and the total asset turnover is 0.57. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.29.
Conclusion
To put it simply, Esperion Therapeutics Inc. (ESPR) has had a better performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
